摘要
晚期卵巢癌患者预后较差,由于缺乏有效的治疗方案,卵巢癌的病死率一直居高不下。聚二磷酸腺苷核糖聚合酶(PARP)抑制剂是一种新型的肿瘤靶向药物,可利用合成致死效应使乳腺癌易感基因(BRCA)突变的肿瘤细胞因无法修复已损伤的DNA而死亡。Olaparib是目前研究最为广泛的PARP抑制剂之一,在欧盟与美国相继上市,用于对铂类敏感、BRCA突变的复发性晚期卵巢癌的支持治疗。近年来,olaparib无论是在单药治疗还是在与细胞毒性化疗药物或分子靶向药物联合治疗晚期卵巢癌的临床试验中,都展现出良好的抗肿瘤效果,可提高患者的无进展生存期(PFS),且患者的耐受性较好,具有良好的应用前景。现就olaparib在晚期卵巢癌治疗中的作用机制、临床试验以及不良反应等方面进行综述。
The patients with advanced ovarian cancer have poor prognosis. The high mortality for patients with advanced ovarian cancer is attributable to the shortage of efficient therapeutic strategies. Poly ADP-ribose polymerase(PARP) inhibitor is a novel type of antineoplastic targeting agent, which can cause BRCA-mutated cancer cells cannot repair the damaged DNA and result in cells death by "synthetic lethality" mechanism. Olaparib is one of the most widely studied PARP inhibitors, which is approved in the European Union and United States for the maintenance treatment of advanced, recurrent ovarian cancer associated with BRCA mutation and platinum sensitivity. Recent clinical trials have demonstrated the effective antineoplastic activity of olaparib as single agents and in combination with cytotoxic chemotherapy and molecular targeted agents, showing an increase of progression free survival(PFS) and well tolerability, exhibiting a promising application prospects. The review discusses the mechanism, clinical trials and adverse effects of olaparib in advanced ovarian tumor treatment.
出处
《国际妇产科学杂志》
CAS
2017年第6期677-680,694,共5页
Journal of International Obstetrics and Gynecology
基金
国家自然科学基金(81472426)
第四轮公共卫生三年行动计划重点学科建设(15GWZK0701)
上海市重中之重临床医学中心项目(2017ZZ02016)
